From owner-7tms_r@net.bio.net Thu Sep 03 23:00:00 1998 Path: biosci!biosci!not-for-mail From: Rick Neubig Newsgroups: bionet.molbio.proteins.7tms_r Subject: ASPET MolPharm Discussion Board Date: 4 Sep 1998 11:50:47 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 40 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6spcq7$rhi@net.bio.net> NNTP-Posting-Host: net.bio.net Dear 7tms readers, I would like to announce a new resource for discussions related to GPCR's and other aspects of signal transduction. The Molecular Pharmacology Division of ASPET is sponsoring a bulletin board covering a number of topics including GPCR's, G proteins, kinases, ion channels, receptor theory, methods, genetic interventions, etc. New conferences can be easily added if there is interest/demand for them. To sign up use your web browser and go to: http://swift.med.umich.edu/~MolPharm and login as a New User to create your own login name and password. A list of conferences hosted by the board is shown on the left and as you open them by expanding the trees you can see the information in the posts inside them. This is just starting up so we welcome active participation. Once you have created your login name and password you can participate in any or all conferences purely by e-mail. Just click the More button at the top and select Mailing Lists from the menu. Check off the mailing lists to which you'd like to belong and you'll get the posts by e-mail with instructions on how to reply by e-mail as well. As this is sponsored by the ASPET Mol Pharm division, I'd also like to invite ASPET members to select the Molecular Pharmacology Division on the annual dues statement when it arrives. Best regards, Rick Neubig Chair, ASPET Molecular Pharmacology Division Executive Committe Rick Neubig RNeubig@umich.edu Department of Pharmacology University of Michigan Phone (734) 763-3650 FAX (734) 763-4450 http://warbler.med.umich.edu From owner-7tms_r@net.bio.net Sun Sep 13 23:00:00 1998 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.molbio.proteins.7tms_r Subject: BIOSCI/bionet miniFAQ & Fundraiser Date: 14 Sep 1998 03:56:01 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 232 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6tiso1$ruj@net.bio.net> NNTP-Posting-Host: net.bio.net (LAST REVISION: 30-JUL-95) This BIOSCI "miniFAQ" is designed to answer the questions that come up the *most frequently*. The main BIOSCI FAQ (Frequently Asked Questions) is accessible on the World Wide Web at URL http://www.bio.net/. If you can not find an answer to your question in this or other documentation, the BIOSCI technical support staff answers e-mail queries sent to biosci-help@net.bio.net We can only answer questions about the use of the newsgroups and mailing lists. We unfortunately do not have the staff to do Internet information searches or answer scientific questions. Please post those to the appropriate BIOSCI/bionet newsgroups. Contents: -------- 0) BIOSCI NEEDS YOUR SUPPORT!! 1) Using the WWW to access the BIOSCI/bionet newsgroups. 2) What to do about "spams," i.e., junk mail, ads, etc. 3) Examples of subscribing and unsubscribing to the mailing lists. 4) The BIOSCI user address and research interest directory. 0) BIOSCI NEEDS YOUR SUPPORT!! - ------------------------------ BIOSCI's government funding has been expended, and we are now operating solely from advertising revenue that we have raised from our Web site at http://www.bio.net/. We need just a few minutes of your time to help us serve you. You can do two important things which will take very little time for you individually and will immensely help us continue to help you. First, please use our WWW system at http://www.bio.net/ to access the archives. You can post or reply to messages via your Web browser as described in item #1 below. Your usage helps attract sponsors. If you contact any of our sponsors, please be sure to thank them for supporting BIOSCI. It is critical for them to get this feedback if they are to continue their sponsorship for the long term. Second, if you work for a company or organization that provides products or services of interest to the biology community, please pass this message on to your marketing or marketing communications department or other appropriate group. Please ask them to help support BIOSCI by sponsoring our Web site and explain the uses and benefits of the system to the biology community. If they are interested, they can then contact us for further information at our tech support address, biosci-help@net.bio.net. 1) Using the WWW to access the BIOSCI/bionet newsgroups. - -------------------------------------------------------- As of 10 December 1995, all BIOSCI/bionet full newsgroups are accessible through the World Wide Web (WWW) at URL http://www.bio.net. One can read and reply publicly or privately to both recent postings and archived messages through one's Web browser if it is configured properly to send e-mail. Each newsgroup is equipped with its own WAIS index. The main BIOSCI home page also has access to the BIO-JOURNALS Table of Contents database WAIS index and the BIOSCI user address database described in another item further below. 2) What to do about "spams," i.e., junk mail, ads, etc. - ------------------------------------------------------- BIOSCI is a set of parallel USENET newsgroups (the "bionet" groups), mailing lists, and a hypermail archive at URL http://www.bio.net/. The same postings are distributed on all media (except for a small number of mailing-list-only groups at net.bio.net). Unfortunately it is becoming a despicable practice on the Internet (by a few people out to make a fast buck) to do automated mass postings to thousands of newsgroups and mailing lists. These attempts to grab free advertising are refered to as "spams" in the usual, somewhat boneheaded, net terminology. USENET is more susceptible to this practice, and many spams originate on the USENET groups and then are passed on to the mailing lists. However, spammers also get lists of mailing addresses and hit these too, so neither medium is immune. What should you do personally if you get junk mail? - --------------------------------------------------- Just delete it and move on without reading it further. Filing a protest is becoming increasingly useless because spammers are often disguising the addresses where the messages are sent from. Unless you really understand Internet mail systems, your attempt at protest by sending replies to the message will often end up being sent to the address of an innocent person that the spammer is victimizing. What can BIOSCI/bionet do to protect its newsgroups? - ---------------------------------------------------- The only solution currently available is to moderate the newsgroup. If this newsgroup is already moderated, then you are in good shape. Moderation protects the USENET distribution from about 95% of the spams that are being sent to date and protects the mailing lists completely. Moderation means, however, that someone has to take the time to review each message before it goes out. We have set up software here that simply allows the moderator to forward to an address at net.bio.net messages that (s)he wishes to have distributed. This takes no more time than that needed to read the message and pass it on, say about 1 min. per message. Most newsgroups currently have a discussion leader who is responsible for their newsgroup. The discussions leaders and their e-mail addresses are listed in the BIOSCI Information Sheet which is available on the Web at http://www.bio.net/. If a newsgroup is being hit with too many junk postings, please contact the discussion leader for that group and see if there is interest in moderating the group. Please do not assume that by simply posting a complaint to the newsgroup itself, anyone on the BIOSCI staff will act on your complaint. With close to 100 newsgroups to run, the BIOSCI staff has to rely on the discussion leaders of each newsgroup to report problems directly to us at biosci-help@net.bio.net. We will moderate any of our newsgroups if the discussion leader tells us that the readership of the group wishes to do so and if a moderator is willing to do the work. For most BIOSCI/bionet groups, this entails only a few minutes of work each day. Moderating a newsgroup will resolve probably 95% of the junk postings on the USENET distribution. Unfortunately there are easy ways for determined spammers to override the moderation mechanism on USENET, but we can protect our e-mail subscribers from unwanted postings if the newsgroup is moderated. You can also access our newsgroups over the WWW at URL http://www.bio.net. While this Web interface will not stop spammers from trying to post to the groups, this will give you yet another way, besides using USENET news, to keep the junk out of your personal mail files. For those of you with local USENET news systems, the Web interface will also give you faster access to new newsgroups and recent postings. 3) Examples of subscribing and unsubscribing to the mailing lists. - ------------------------------------------------------------------ PLEASE NOTE: The BIOSCI management does NOT act on subscription/unsubscription requests that are posted improperly to the newsgroups and mailing lists. People who do this only bother everyone on the lists to no avail. Please be sure to follow the proper procedures below. Gory details are in the BIOSCI Information sheets on the Web at http://www.bio.net. Below we give an example utilizing the METHODS-AND-REAGENTS list at both of our two BIOSCI sites: Users in the Americas and Pacific Rim countries who use the BIOSCI - ------------------------------------------------------------------ node at computer net.bio.net: - ---------------------------- A) Determine the "listname" which is the <=8 character mail address ^^^^^^^^^^^^^ for the group. These can be found in the BIOSCI Info. Sheet. For the METHODS-AND-REAGENTS group the mailing address is methods@net.bio.net. The listname is the portion of the address to the left of the @ sign, i.e., "methods". The listname is used with the "subscribe" and "unsubscribe" commands illustrated below. B) Mail all commands in the body of a mail message addressed to biosci-server@net.bio.net. Do NOT send commands to the newsgroup posting addresses! Leave the Subject: line blank, any text on it will be ignored. C) In the body of your message put one or more of the following commands with an "end" command on the last line, e.g., subscribe methods unsubscribe methods end Do NOT put your e-mail address or other text on these lines. The server only allows you to cancel your subscription if the address on your mail header matches the address on our mailing list. Please ask for help at biosci-help@net.bio.net if your address has changed, e.g., if you know you are on the list but the server tells you that you are not a member. Users in Europe, Africa, and Central Asia who use the BIOSCI node at - -------------------------------------------------------------------- computer daresbury.ac.uk (also known as dl.ac.uk): - ------------------------------------------------- To subscribe and unsubscribe to/from the BIOSCI lists, you need to specify the full USENET newsgroup name with "bionet-news." prepended. The USENET newsgroup names are listed in the BIOSCI Information sheet on the Web at http://www.bio.net/. For the METHODS-AND-REAGENTS list the USENET newsgroup name is bionet.molbio.methds-reagnts, thus the appropriate commands are sub bionet-news.bionet.molbio.methds-reagnts unsub bionet-news.bionet.molbio.methds-reagnts These commands are included in a message addressed to mxt@dl.ac.uk, NOT to the newsgroup mailing addresses. As usual, include the text in the body of the message as text on the Subject: line is ignored. To unsubscribe from all the lists at the UK node, use unsub bionet-news Please note that if the address in the list is different than the one in your mail message header, you will not be able to unsubscribe by this method. If you have problems, please mail biosci@daresbury.ac.uk. 4) The BIOSCI user address and research interest directory. - ----------------------------------------------------------- Please take this opportunity to add your name, address, and research interest information to the BIOSCI User Address Database if you have not already done so. You can fill out the address form directly through our Web page at URL http://www.bio.net/adrform.html. The address database is reindexed nightly for WWW access (the URL is http://www.bio.net/). If you are not directly on the Internet but can reach it by e-mail, please use our waismail server to access the user directory. waismail use is described above. You can also request a user address form by e-mail from biosci-help@net.bio.net. Please check your database entry from time-to-time to see if your address information is still up-to-date. Because of our limited personnel resources, we ask that you resubmit a *complete* form to revise your entry; we only replace complete entries and do not have resources to edit old forms. From owner-7tms_r@net.bio.net Mon Sep 21 23:00:00 1998 Path: biosci!biosci!not-for-mail From: Ken Minneman Newsgroups: bionet.molbio.proteins.7tms_r Subject: Postdoctoral Position Available Date: 22 Sep 1998 07:32:47 -0700 Organization: Emory University Lines: 16 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6u8cef$8qc@net.bio.net> NNTP-Posting-Host: net.bio.net An NIH funded postdoctoral position is available immediately in my laboratory. We are studying nontraditional signaling pathways activated by adrenergic receptor subtypes. We are focusing particularly on mitogenic responses, using transfected PC12 cells as a model system. More information about our laboratory, funding, publications, and research environment is available at http://www.emory.edu/PHARMACOLOGY/MINNEMAN/ Interested applicants please contact me at kminneman@pharm.emory.edu Kenneth P. Minneman, Ph.D Professor of Pharmacology Emory University From owner-7tms_r@net.bio.net Tue Sep 22 23:00:00 1998 Path: biosci!biosci!not-for-mail From: ralf jockers Newsgroups: bionet.molbio.proteins.7tms_r Subject: post-doctoral position Date: 23 Sep 1998 06:36:01 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 156 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6uatg1$jmr@net.bio.net> NNTP-Posting-Host: net.bio.net - --============_-1305637228==_============ Content-Type: text/plain; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Dear Sir, Please find enclosed our announcement for a post-doctoral position which should be relevant for people connected to this newsgroup. You will find the message as attached file (Word 5.1 for Mac) as well as part of this e-mail. If you have any problems will the treatment of the text please do not hesitate to contact me. Sincerely yours Dr. Ralf Jockers Message: Postdoctoral position in PARIS at Institut Cochin de G=E9n=E9tique Mol=E9cul= aire for Biochemists/Pharmacologists The Institut Cochin was founded in 1989 on the campus of the Cochin Hospital to promote interactions between fundamental and clinical science. The Institut Cochin is located in the heart of Paris (France), is equipped with state-of-art facilities and operates in an outstanding research environment (research triangle Institut Pasteur - Institut Curie - Institut Cochin). The "Laboratoire d'Immuno-Pharmacologie Mol=E9culaire" directed by Dr. AD Strosberg, hosts 50 scientists and seven groups working on different aspects of G protein-coupled receptor signaling (see http://www.cochin.inserm.fr/upr415/index.htm). A high percentage of foreign post-docs and Phd students explains its very international atmosphere. We are looking for a post-doc with experience in techniques of molecular biology, protein chemistry, or biochemical pharmacology as well as enthusiasm and ambition who like to join our young research group on the "Regulation of G protein-coupled receptors". The projects focus on two model receptors, =DF-adrenergic receptors (=DFAR) and melatonin receptors (MelR). We are interested in the molecular mechanisms of =DFAR regulation a topic developed in our lab for more than on= e decade. The second more recent topic is the function and regulation of MelR which play a major role in circadian rhythms and reproduction. Our group participated in the recent cloning of these receptors and is now interested in the molecular aspects involved in their functions. Candidates are expected to obtain a post-doctoral research fellowship. Of course, we will be happy to give you any possible assistance for your application. Please send CV to: Dr. Ralf JOCKERS INSTITUT COCHIN DE GENETIQUE MOLECULAIRE Lab. d'Immuno-Pharmacologie. Mol=E9culaire. 22 rue Mechain 75014 Paris, France e-mail: jockers@icgm.cochin.inserm.fr Tel: 1.40.51.64.34 =46ax:1.40.51.72.10 - --============_-1305637228==_============ Content-Type: application/msword; name="Position2.doc" ; x-mac-type="5744424E" ; x-mac-creator="4D535744" Content-Disposition: attachment; filename="Position2.doc" Content-Transfer-Encoding: base64 /jcAIwAAAAAAAAQAABkAAAAAAAAAAAEAAAAIuQAAD4gAAAAAAAAHuQAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAADgAAGwAADgAAGwAADhsAAAAADhsAAAAADhsADgAADikAEgAA DjsAAAAADjsAAAAADjsAAAAADjsACgAADkUACgAADk8AAAAADk8AHgAADm0AeAAADjsA AAAADuUAIAAADwUAGAAAD0YAKgAAD3AAAAAADhsAAAABAAEAAA88AAIAAA8dAB8AAA8+ AAQAAA9CAAQAAA9wABgAAA9GAAAAAA9GAAAAAA9GAAAAAA9GAAAAAA9GAAAAAA9GAAAA AA1Qb3N0ZG9jdG9yYWwgcG9zaXRpb24NaW4gUEFSSVMNYXQgSW5zdGl0dXQgQ29jaGlu IGRlIEeObo50aXF1ZSBNb2yOY3VsYWlyZQ0gZm9yIEJpb2NoZW1pc3RzL1BoYXJtYWNv bG9naXN0cw0NCVRoZSBJbnN0aXR1dCBDb2NoaW4gd2FzIGZvdW5kZWQgaW4gMTk4OSBv biB0aGUgY2FtcHVzIG9mIHRoZSBDb2NoaW4gSG9zcGl0YWwgdG8gcHJvbW90ZSBpbnRl cmFjdGlvbnMgYmV0d2VlbiBmdW5kYW1lbnRhbCBhbmQgY2xpbmljYWwgc2NpZW5jZS4g VGhlIEluc3RpdHV0IENvY2hpbiBpcyBsb2NhdGVkIGluIHRoZSBoZWFydCBvZiBQYXJp cyAoRnJhbmNlKSwgaXMgZXF1aXBwZWQgd2l0aCBzdGF0ZS1vZi1hcnQgZmFjaWxpdGll cyBhbmQgb3BlcmF0ZXMgaW4gYW4gb3V0c3RhbmRpbmcgcmVzZWFyY2ggZW52aXJvbm1l bnQgKHJlc2VhcmNoIHRyaWFuZ2xlIEluc3RpdHV0IFBhc3RldXIgLSBJbnN0aXR1dCBD dXJpZSAtIEluc3RpdHV0IENvY2hpbikuIA0NCVRoZSAiTGFib3JhdG9pcmUgZCdJbW11 bm8tUGhhcm1hY29sb2dpZSBNb2yOY3VsYWlyZSIgZGlyZWN0ZWQgYnkgRHIuIEFEIFN0 cm9zYmVyZywgaG9zdHMgNTAgc2NpZW50aXN0cyBhbmQgc2V2ZW4gZ3JvdXBzIHdvcmtp bmcgb24gZGlmZmVyZW50IGFzcGVjdHMgb2YgRyBwcm90ZWluLWNvdXBsZWQgcmVjZXB0 b3Igc2lnbmFsaW5nIChzZWUgaHR0cDovL3d3dy5jb2NoaW4uaW5zZXJtLmZyL3VwcjQx NS9pbmRleC5odG0pLiBBIGhpZ2ggcGVyY2VudGFnZSBvZiBmb3JlaWduIHBvc3QtZG9j cyBhbmQgUGhkIHN0dWRlbnRzIGV4cGxhaW5zIGl0cyB2ZXJ5IGludGVybmF0aW9uYWwg YXRtb3NwaGVyZS4gDQ0JV2UgYXJlIGxvb2tpbmcgZm9yIGEgcG9zdC1kb2Mgd2l0aCBl eHBlcmllbmNlIGluIHRlY2huaXF1ZXMgb2YgbW9sZWN1bGFyIGJpb2xvZ3ksIHByb3Rl aW4gY2hlbWlzdHJ5LCBvciBiaW9jaGVtaWNhbCBwaGFybWFjb2xvZ3kgYXMgd2VsbCBh cyBlbnRodXNpYXNtIGFuZCBhbWJpdGlvbiB3aG8gbGlrZSB0byBqb2luIG91ciB5b3Vu ZyByZXNlYXJjaCBncm91cCBvbiB0aGUgIlJlZ3VsYXRpb24gb2YgRyBwcm90ZWluLWNv dXBsZWQgcmVjZXB0b3JzIi4NDQlUaGUgcHJvamVjdHMgZm9jdXMgb24gdHdvIG1vZGVs IHJlY2VwdG9ycywgpy1hZHJlbmVyZ2ljIHJlY2VwdG9ycyAop0FSKSBhbmQgbWVsYXRv bmluIHJlY2VwdG9ycyAoTWVsUikuIFdlIGFyZSBpbnRlcmVzdGVkIGluIHRoZSBtb2xl Y3VsYXIgbWVjaGFuaXNtcyBvZiCnQVIgcmVndWxhdGlvbiBhIHRvcGljIGRldmVsb3Bl ZCBpbiBvdXIgbGFiIGZvciBtb3JlIHRoYW4gb25lIGRlY2FkZS4gVGhlIHNlY29uZCBt b3JlIHJlY2VudCB0b3BpYyBpcyB0aGUgZnVuY3Rpb24gYW5kIHJlZ3VsYXRpb24gb2Yg TWVsUiB3aGljaCBwbGF5IGEgbWFqb3Igcm9sZSBpbiBjaXJjYWRpYW4gcmh5dGhtcyBh bmQgcmVwcm9kdWN0aW9uLiBPdXIgZ3JvdXAgcGFydGljaXBhdGVkIGluIHRoZSByZWNl bnQgY2xvbmluZyBvZiB0aGVzZSByZWNlcHRvcnMgYW5kIGlzIG5vdyBpbnRlcmVzdGVk IGluIHRoZSBtb2xlY3VsYXIgYXNwZWN0cyBpbnZvbHZlZCBpbiB0aGVpciBmdW5jdGlv bnMuDQ0JQ2FuZGlkYXRlcyBhcmUgZXhwZWN0ZWQgdG8gb2J0YWluIGEgcG9zdC1kb2N0 b3JhbCByZXNlYXJjaCBmZWxsb3dzaGlwLiBPZiBjb3Vyc2UsIHdlIHdpbGwgYmUgaGFw cHkgdG8gZ2l2ZSB5b3UgYW55IHBvc3NpYmxlIGFzc2lzdGFuY2UgZm9yIHlvdXIgYXBw bGljYXRpb24uDQ1QbGVhc2Ugc2VuZCBDViB0bzoNRHIuIFJhbGYgSk9DS0VSUw1JTlNU SVRVVCAgQ09DSElOIERFICBHRU5FVElRVUUgIE1PTEVDVUxBSVJFDUxhYi4gZCdJbW11 bm8tUGhhcm1hY29sb2dpZS4gTW9sjmN1bGFpcmUuDTIyIHJ1ZSBNZWNoYWluDTc1MDE0 IFBhcmlzLCBGcmFuY2UNZS1tYWlsOiBqb2NrZXJzQGljZ20uY29jaGluLmluc2VybS5m cg1UZWw6IDEuNDAuNTEuNjQuMzQNRmF4OjEuNDAuNTEuNzIuMTANDQ51AHgC4YIBaIME boQEboBEZ0RwABAHIEzliNHACCgABgvKZwZwINBFYAIwBT1A//5wABAGIEzliNHACCgA BgvKZwZwINBEYAIwBLBu//5noDAFkERgAnAATN8A8E5eTnVOVv8ASOcDECZuABQvLgAM Trr+th4ALq4AGC8uABAvLgAMLy4ACE6sH7gcAE/vABBnJi8LSG7/ACBuABA/EC8uAAhO rB/IvisAAk/vAA5kBHwAYAQXRwACEAZM3wjATl5OdU5W//5I5wMwLi4ACCZuAAwsLgAQ SoZnBCBGQhAgRyRQYA5KhmcIEC7//yBGgRBSirfKYxRIbv//LwsvCk6sIIhKAE/vAAxm 2rfKYgRwAGBQSG7//y8LLwpOrCCISoZP7wAMZwgQLv//IEaBECBHIIpgEEquABRnCCBu ABQQrv//Uoq3ygAAAQAAAAEBAAABIwAAAUwAAAFsAAABbQAACLgAAAi5AAAIyPr07vTt 5+TeAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAoAQAAC GAAAAAAYAASAEADJAAoACAAAGAAAAAAYAAGACsAIAAAkAAAAACQACoAIAAAkAAAAACQA CgAIAAAkAAAAACQIAAABAAAAAQEAAAEXAAABIAAAAUwAAAFtAAABbgAAAuQAAALlAAAE PAAABD0AAAVAAAAFQQAABzAAAAcxAAAHzwAAB9AAAAfjAAAH9AAACCAAAAhKAAAIWQAA CG0AAAiTAAAIpgAACLgAAAi5+fn5+fn07+rv6uXq4Orb9OrV1dXV1dXV1dUAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAABQAAAAAAAAAQ/xQABAAAAiNkAAwA AAQAAAYjZAAMAAAEAAADI2QADAAABAAAASNkAAwAAAQAAAQjZAAMAAAEAAAAAAAAAAAA BgAAASNkABgFARQB4BoAAAADAAAIBQAYABQUAAoHAAAAAAAAAAABAN4AAAAAAAAHuQAE AAAIuQAAAAAAAAe5UAD//wAAAAEAAAAAAQAAAAjIAAUAAAEAAAAIuQAGAAAAAgADAAQA DQAQABQAFQAWABcAyADJAQAH2AfbAAMAAABIAEgAAAAAAw0CGv/i/+MDLAI2A0cFewPg AAIAAABIAEgAAAAAAw0CGgABAAAAZAAAAAEAAwMDAP8AAScPAAEAAQAAAAAAAAAAAAAA AGAYABkBkAAAAAAAAAAAAAAAAAAAAAEAAAAAAAAAAAAAAAAAAAAAQcgufAWJBYoFiQWK AAAA4xIAAAEAAQABAAAAAAAAAEgAGA8tOkxhc2VyV3JpdGVyIDgACgAAAAAAAgAAABQF VGltZXMAAADJDk1pc2hhd2FrYSBCb2xkAAIAAAe5AAAHuYABAAAAAAe4AAAHuAAHgACA AAAAB7gAAAAAAC0BJQJyAzQAKAACAUICEQAYCnNhbnN0aXRyZTIAB2pvY2tlcnMAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAA== - --============_-1305637228==_============-- From owner-7tms_r@net.bio.net Tue Sep 22 23:00:00 1998 Path: biosci!biosci!not-for-mail From: Alessandro Giolitti Newsgroups: bionet.molbio.proteins.7tms_r Subject: Tritiated compounds Date: 23 Sep 1998 06:37:17 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 23 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6uatid$juu@net.bio.net> NNTP-Posting-Host: net.bio.net Hi all: we have a problem. It is nice to have tritiated compounds for binding studies on mutated receptors and so on. This kind of labeling is easier and cheaper than others, and works quite well. Now, the problem: we used to have our compounds labeled by SibTech, which is now moving and not able for a while to deliver. Is some of you aware of other companies which could tritiate compounds? Thanks a lot for your help, Alessandro Giolitti ______________________________________________________________________________ Dr. Alessandro Giolitti Head of Drug Design Ph. : +39-55-5680240 Menarini Ricerche S.p.A. FAX : +39-55-5680419 Via Sette Santi, 3 50131 Firenze e-mail: agiolitti@menarini-ricerche.it lns@dada.it Italy ______________________________________________________________________________ From owner-7tms_r@net.bio.net Thu Sep 24 23:00:00 1998 Path: biosci!biosci!not-for-mail From: "Paul Ernsberger, Ph.D." Newsgroups: bionet.molbio.proteins.7tms_r Subject: RE: Tritiated compounds Date: 25 Sep 1998 16:02:08 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 48 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6uh7dg$5lo@net.bio.net> NNTP-Posting-Host: net.bio.net I have used both NEN/DuPont and Amersham for custom tritiation. NEN/DuPont does better chemistry and purification. Both are extremely expensive. I have never heard of SibTech. \/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\ Paul Ernsberger, PhD, Department of Nutrition, Case Western Reserve School of Medicine, 10900 Euclid Ave., Cleveland, OH 44106-4906 Web address: http://www.cwru.edu/med/nutrition/ernsberger.htm Email: pre@po.cwru.edu; FAX: (216) 368-4752 |-----Original Message----- |From: Alessandro Giolitti [mailto:lns@dada.it] |Sent: Wednesday, September 23, 1998 1:29 AM |To: nobody@net.bio.net |Subject: Tritiated compounds | | |Hi all: | | we have a problem. It is nice to have tritiated compounds for binding |studies on mutated receptors and so on. This kind of labeling |is easier and |cheaper than others, and works quite well. Now, the problem: we used to |have our compounds labeled by SibTech, which is now moving and |not able for |a while to deliver. |Is some of you aware of other companies which could tritiate compounds? | |Thanks a lot for your help, | |Alessandro Giolitti |_______________________________________________________________ |_______________ | | Dr. Alessandro Giolitti | Head of Drug Design Ph. : +39-55-5680240 | Menarini Ricerche S.p.A. FAX : +39-55-5680419 | Via Sette Santi, 3 | 50131 Firenze e-mail: |agiolitti@menarini-ricerche.it | lns@dada.it | Italy | |_______________________________________________________________ |_______________ |